FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123786180> ?p ?o ?g. }

• W2123786180 endingPage "103" @default.
• W2123786180 startingPage "90" @default.
• W2123786180 abstract "A bstract : Neuroectodermal tumors are highly malignant and increasingly common tumors. Because the cure rate of these neoplasias by conventional treatment is very low, new therapeutic approaches are needed. Entrapping high concentrations of cytotoxic drugs and/or oligonucleotides within stabilized liposomal formulations represents an emerging modality of antitumor treatment. Here, we tested the in vitro and in vivo antitumor effects of a novel antisense oligodeoxynucleotide (asODN) liposomal formulation, the coated cationic liposomes (CCL), by targeting the c‐myc and the c‐myb oncogenes on melanoma and neuroblastoma, respectively, through the use of a monoclonal antibody against the disialoganglioside GD 2 , selectively expressed by neuroectoderma‐derived tumors. Our methods produced GD 2 ‐targeted liposomes that stably entrapped 90 percent of added asODNs. These liposomes showed selective binding for GD 2 ‐positive tumor cells in vitro . Neuroblastoma cells treated with free myb‐as or nontargeted CCL‐myb‐as showed the same level of c‐myb protein expression as control cells. In contrast, c‐myb protein expression of cells treated with aGD 2 ‐CCL‐myb‐as was inhibited by approximately 70 percent. Melanoma and neuroblastoma cell proliferation was inhibited to a greater extent by GD 2 ‐targeted liposomes containing c‐myc or c‐myb asODNs than by nontargeted liposomes or free asODNs. Mice bearing established subcutaneous human melanoma xenografts treated with aGD 2 ‐CCL‐myc‐as exhibited significantly reduced tumor growth and increased survival. The mechanism for the antitumor effects appears to be downregulation of the expression of the c‐myc protein, induction of p53, and inhibition of Bcl‐2 proteins, leading to extensive tumor cell apoptosis. In contrast, the increased life span obtained in a neuroblastoma pseudometastatic mouse model with the liposomal c‐myb asODNs seems to be due to a synergistic mechanism: specific targeting to neuroblastoma cancer cells, downmodulation of c‐myb protein expression, and stimulation of the innate immune system. These results suggest that inhibition of c‐myc or c‐myb proto‐oncogenes by GD 2 ‐targeted antisense therapy could provide an effective approach for the treatment of neuroectodermal tumors in an adjuvant setting." @default.
• W2123786180 created "2016-06-24" @default.
• W2123786180 creator A5000242295 @default.
• W2123786180 creator A5013539213 @default.
• W2123786180 creator A5015444918 @default.
• W2123786180 creator A5035931487 @default.
• W2123786180 creator A5041501501 @default.
• W2123786180 creator A5053922930 @default.
• W2123786180 creator A5070686436 @default.
• W2123786180 date "2004-12-01" @default.
• W2123786180 modified "2023-09-24" @default.
• W2123786180 title "Targeted Delivery of Oncogene-Selective Antisense Oligonucleotides in Neuroectodermal Tumors: Therapeutic Implications" @default.
• W2123786180 cites W1520954846 @default.
• W2123786180 cites W1951128322 @default.
• W2123786180 cites W1976048604 @default.
• W2123786180 cites W1992578082 @default.
• W2123786180 cites W1999855196 @default.
• W2123786180 cites W2003717137 @default.
• W2123786180 cites W2011386610 @default.
• W2123786180 cites W2018229773 @default.
• W2123786180 cites W2030534890 @default.
• W2123786180 cites W2068508373 @default.
• W2123786180 cites W2130227763 @default.
• W2123786180 cites W2239046105 @default.
• W2123786180 cites W2327401507 @default.
• W2123786180 cites W3026227968 @default.
• W2123786180 doi "https://doi.org/10.1196/annals.1322.010" @default.
• W2123786180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15650235" @default.
• W2123786180 hasPublicationYear "2004" @default.
• W2123786180 type Work @default.
• W2123786180 sameAs 2123786180 @default.
• W2123786180 citedByCount "15" @default.
• W2123786180 countsByYear W21237861802014 @default.
• W2123786180 countsByYear W21237861802015 @default.
• W2123786180 countsByYear W21237861802016 @default.
• W2123786180 countsByYear W21237861802017 @default.
• W2123786180 countsByYear W21237861802019 @default.
• W2123786180 crossrefType "journal-article" @default.
• W2123786180 hasAuthorship W2123786180A5000242295 @default.
• W2123786180 hasAuthorship W2123786180A5013539213 @default.
• W2123786180 hasAuthorship W2123786180A5015444918 @default.
• W2123786180 hasAuthorship W2123786180A5035931487 @default.
• W2123786180 hasAuthorship W2123786180A5041501501 @default.
• W2123786180 hasAuthorship W2123786180A5053922930 @default.
• W2123786180 hasAuthorship W2123786180A5070686436 @default.
• W2123786180 hasConcept C104317684 @default.
• W2123786180 hasConcept C127561419 @default.
• W2123786180 hasConcept C129312508 @default.
• W2123786180 hasConcept C1491633281 @default.
• W2123786180 hasConcept C150903083 @default.
• W2123786180 hasConcept C153911025 @default.
• W2123786180 hasConcept C155887181 @default.
• W2123786180 hasConcept C185154212 @default.
• W2123786180 hasConcept C185592680 @default.
• W2123786180 hasConcept C202751555 @default.
• W2123786180 hasConcept C207001950 @default.
• W2123786180 hasConcept C2776715637 @default.
• W2123786180 hasConcept C2777658100 @default.
• W2123786180 hasConcept C2781018059 @default.
• W2123786180 hasConcept C29537977 @default.
• W2123786180 hasConcept C502942594 @default.
• W2123786180 hasConcept C54009773 @default.
• W2123786180 hasConcept C54355233 @default.
• W2123786180 hasConcept C552990157 @default.
• W2123786180 hasConcept C55493867 @default.
• W2123786180 hasConcept C81885089 @default.
• W2123786180 hasConcept C86803240 @default.
• W2123786180 hasConceptScore W2123786180C104317684 @default.
• W2123786180 hasConceptScore W2123786180C127561419 @default.
• W2123786180 hasConceptScore W2123786180C129312508 @default.
• W2123786180 hasConceptScore W2123786180C1491633281 @default.
• W2123786180 hasConceptScore W2123786180C150903083 @default.
• W2123786180 hasConceptScore W2123786180C153911025 @default.
• W2123786180 hasConceptScore W2123786180C155887181 @default.
• W2123786180 hasConceptScore W2123786180C185154212 @default.
• W2123786180 hasConceptScore W2123786180C185592680 @default.
• W2123786180 hasConceptScore W2123786180C202751555 @default.
• W2123786180 hasConceptScore W2123786180C207001950 @default.
• W2123786180 hasConceptScore W2123786180C2776715637 @default.
• W2123786180 hasConceptScore W2123786180C2777658100 @default.
• W2123786180 hasConceptScore W2123786180C2781018059 @default.
• W2123786180 hasConceptScore W2123786180C29537977 @default.
• W2123786180 hasConceptScore W2123786180C502942594 @default.
• W2123786180 hasConceptScore W2123786180C54009773 @default.
• W2123786180 hasConceptScore W2123786180C54355233 @default.
• W2123786180 hasConceptScore W2123786180C552990157 @default.
• W2123786180 hasConceptScore W2123786180C55493867 @default.
• W2123786180 hasConceptScore W2123786180C81885089 @default.
• W2123786180 hasConceptScore W2123786180C86803240 @default.
• W2123786180 hasIssue "1" @default.
• W2123786180 hasLocation W21237861801 @default.
• W2123786180 hasLocation W21237861802 @default.
• W2123786180 hasOpenAccess W2123786180 @default.
• W2123786180 hasPrimaryLocation W21237861801 @default.
• W2123786180 hasRelatedWork W1561441286 @default.
• W2123786180 hasRelatedWork W1984816716 @default.
• W2123786180 hasRelatedWork W2020692772 @default.
• W2123786180 hasRelatedWork W2030627242 @default.

• next